Abstract:With the success of immunotherapy in other oncology areas, prostate cancer has also entered the era of immunotherapy. At present, the immune checkpoints (ICs) in the prostate cancer field have been studied deeply, including CTLA-4 and PD-1/PD-L1 pathways. This article reviews the recent progress of immune checkpoint inhibitors (ICIs) monotherapy or combination therapy in patients with advanced prostate cancer, and discusses its development direction and application prospect.
吕泉龙 史文杰 孙文国. 免疫检查点抑制剂在治疗转移性去势抵抗性
前列腺癌中的研究进展[J]. 中华诊断学电子杂志, 2024, 12(1): 69-72.
Lyu Quanlong, Shi Wenjie, Sun Wenguo. Research advances of immune checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer. zhzdx, 2024, 12(1): 69-72.
[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.DOI:10.3322/caac.21660.
[2]Parker C,Castro E,Fizazi K,et al.Prostate cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2020,31(9):1119-1134.DOI:10.1016/j.annonc.2020.06.011.
[3]Cornford P,van den Bergh R,Briers E,et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer.Part II-2020 update:treatment of relapsing and metastatic prostate cancer[J].Eur Urol,2021,79(2):263-282.DOI:10.1016/j.eururo.2020.09.046.
[4]孔琪,王章桂.晚期前列腺癌治疗进展[J].实用医学杂志,2021,37(3):410-414.DOI:10.3969/j.issn.1006-5725.2021.01.027.
[5]Nuhn P,De Bono JS,Fizazi K,et al.Update on systemic prostate cancer therapies:management of metastatic castration-resistant prostate cancer in the era of precision oncology[J].Eur Urol,2019,75(1):88-99.DOI:10.1016/j.eururo.2018.03.028.
[6]宋若飘,臧爱民,贾友超.PD-L1在肿瘤细胞中表达调控机制研究进展[J].实用医学杂志,2020,36(10):1286-1291.DOI:10.3969/j.issn.1006-5725.2020.10.005.
[7]Farhangnia P,Ghomi SM,Akbarpour M,et al.Bispecific antibodies targeting CTLA-4:game-changer troopers in cancer immunotherapy[J].Front Immunol,2023(14):1155778.DOI:10.3389/fimmu.2023.1155778.
[8]Isaacsson Velho P,Antonarakis ES.PD-1/PD-L1 pathway inhibitors in advanced prostate cancer[J].Expert Rev Clin Pharmacol,2018,11(5):475-486.DOI:10.1080/17512433.2018.1464388.
[9]Xu Y, Song G, Xie S, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer[J].Mol Ther,2021,29(6):1958-1969.DOI:10.1016/j.ymthe.2021.04.029.
[10]Hossen MM,Ma Y,Yin Z,et al.Current understanding of CTLA-4:from mechanism to autoimmune diseases[J].Front Immunol,2023(14):1198365.DOI:10.3389/fimmu.2023.1198365.
[11]Wei SC,Duffy CR,Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer Discov,2018,8(9):1069-1086.DOI:10.1158/2159-8290.CD-18-0367.
[12]Kwon J,Bryant RJ,Parkes EE.The tumor microenvironment and immune responses in prostate cancer patients[J].Endocr Relat Cancer,2021,28(8):T95-T107.DOI:10.1530/ERC-21-0149.
[13]Subudhi SK,Vence L,Zhao H,et al.Neoantigen responses,immune correlates,and favorable outcomes after ipilimumab treatment of patients with prostate cancer[J].Sci Transl Med,2020,12(537):eaaz3577 [pii].DOI:10.1126/scitranslmed.aaz3577.
[14]Kwon ED,Drake CG,Scher HI,et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712.DOI:10.1016/S1470-2045(14)70189-5.
[15]Fizazi K,Drake CG,Beer TM,et al.Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors[J].Eur Urol,2020,78(6):822-830.DOI:10.1016/j.eururo.2020.07.032.
[16]Beer TM,Logothetis C,Sharma P,et al.CA184-095:a randomized,double-blind,phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)[J].J Clin Oncol,2013,31(1):15-16.DOI:10.1186/1477-7819-11-101.
[17]Beer TM,Kwon ED,Drake CG,et al.Randomized,double-blind,phase Ⅲ trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer[J].J Clin Oncol,2017,35(1):40-47.DOI:10.1200/JCO.2016.69.1584.
[18]Jafari S,Molavi O,Kahroba H,et al.Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer[J].Cell Mol Life Sci,2020,77(19):3693-3710.DOI:10.1007/s00018-020-03459-1.
[19]Antonarakis ES,Piulats JM,Gross-Goupil M,et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort,open-label phase Ⅱ KEYNOTE-199 study[J].J Clin Oncol,2020,38(5):395-405.DOI:10.1200/JCO.19.01638.
[20]Abida W,Cheng ML,Armenia J,et al.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade[J].JAMA Oncol,2019,5(4):471-478.DOI:10.1001/jamaoncol.2018.5801.
[21]Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA[J].J Immunother Cancer,2020,8(2):e001065.DOI:10.1136/jitc-2020-001065.
[22]Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer:response to PD-1 blockade and standard therapies[J].PLoS One,2020,15(5):e0233260.DOI:10.1371/journal.pone.0233260.
[23]Hansen AR,Massard C,Ott PA,et al.Pembrolizumab for advanced prostate adenocarcinoma:findings of the KEYNOTE-028 study[J].Ann Oncol,2018,29(8):1807-1813.DOI:10.1093/annonc/mdy232.
[24]Petrylak DP,Loriot Y,Shaffer DR,et al.Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer:a phase i study[J].Clin Cancer Res,2021,27(12):3360-3369.DOI:10.1158/1078-0432.CCR-20-1981.
[25]Vitkin N, Nersesian S, Siemens DR, et al. The tumor immune contexture of prostate cancer[J].Front Immunol,2019(10):603.DOI:10.3389/fimmu.2019.00603.
[26]Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer:preliminary analysis of patients in the checkmate 650 trial[J].Cancer Cell,2020,38(4):489-499.e3.DOI:10.1016/j.ccell.2020.08.007.
[27]Long X,Hou H,Wang X,et al.Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration[J].Cell Death Dis,2020,11(9):779.DOI:10.1038/s41419-020-02973-1.
[28]Graff JN, Antonarakis ES, Hoimes CJ, et al. Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC):KEYNOTE-199 cohorts 4-5[J].J Clini Oncol,2020,38(6_suppl):15.DOI:10.1200/JCO.2020.38.6_suppl.15.
[29]Graff JN,Beer TM,Alumkal JJ,et al.A phase Ⅱ single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone[J].J Immunother Cancer,2020,8(2):e000642.DOI:10.1136/jitc-2020-000642.
[30]Petrylak DP,Ratta R,Gafanov R,et al.KEYNOTE-921:phase Ⅲ study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer[J].Future Oncol,2021,17(25):3291-3299.DOI:10.2217/fon-2020-1133.
[31]Petrylak DP,Li B,Schloss C,et al.KEYNOTE-921:Phase Ⅲ study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)[J].Ann Onco,2019,30(Supplement_5):v351.DOI:10.1093/annonc/mdz248.048.
[32]Drake CG,Saad F,Clark WR,et al.690TiP a phase Ⅲ,randomized,double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX) - ScienceDirect[J].Ann Oncol,2020,31(4):S546.DOI:10.1016/j.annonc.2020.08.2084.
[33]Liu D.CAR-T "the living drugs",immune checkpoint inhibitors,and precision medicine:a new era of cancer therapy[J].J Hematol Oncol,2019,12(1):113.DOI:10.1186/s13045-019-0819-1.
[34]Sam J,Colombetti S,Fauti T,et al.Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity[J].Front Oncol,2020(10):575737.DOI:10.3389/fonc.2020.575737.
[35]Daver N.A bispecific approach to improving CAR T cells in AML[J].Blood,2020,135(10):703-704.DOI:10.1182/blood.2020004791.
[36]Agarwal N,McGregor B,Maughan BL,et al.Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer:results from an expansion cohort of a multicentre,open-label,phase 1b trial (COSMIC-021)[J].Lancet Oncol,2022,23(7):899-909.DOI:10.1016/S1470-2045(22)00278-9.
[37]Cattrini C,Espaa R,Mennitto A,et al.Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer[J].Cancers (Basel),2021,13(18):4522.DOI:10.3390/cancers13184522.